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Background: Hepatocellular carcinoma (HCC) is a common malignancy worldwide, which is especially prevalent in
Asia. Elucidating the molecular basis of HCC is crucial to develop targeted diagnostic tools and novel therapies.
Recent studies have identified AT-rich interactive domain-containing protein 1A (ARID1A) as a broad-spectrum
tumor suppressor. We evaluated the clinical implications of decreased ARID1A expression in HCC, and investigated
the mechanisms of ARID1A-mediated tumor suppression.
Methods: Quantitative PCR, western blotting, immunohistochemical analysis of ARID1A mRNA and protein
expression was conducted in 64 paired HCC and adjacent non-tumorous tissues. ARID1A function was evaluated
in vitro in MHCC-97H and Huh7 HCC cell lines, and in vivo in a xenografted HCC tumor model.
Results: ARID1A mRNA and protein expression were significantly decreased in HCC tissues, and decreased
expression was significantly associated with overall metastasis, including local lymph node and distant metastasis,
and poor prognosis. ARID1A knockdown promoted HCC cell migration and invasion in vitro, whereas
overexpression of ARID1A inhibited migration and invasion. E-cadherin levels were closely correlated with ARID1A
expression, suggesting a role in migration and invasion. In addition, ARID1A and E-cadherin (CDH1) expression were
found to be regulated in a coordinated fashion in HCC samples. Furthermore, ARID1A knockdown significantly increased
HCC tumor growth and lung metastasis in vivo.
Conclusions: ARID1A served as an important tumor suppressor. Decreased expression of ARID1A was associated with
tumor progression, metastasis, and reduced overall survival in mice and humans. ARID1A could represent a promising
candidate therapeutic target for HCC.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide, and is especially
prevalent in Asia [1]. Existing therapies are insufficient
for complete tumor eradication. Elucidating the molecu-
lar basis of HCC is crucial to develop targeted diagnostic
tools and therapies [2]. Genetic lesions play a major role
in HCC tumorigenesis and progression. Recently, cancer
genome sequencing has identified frequent mutations in
epigenetic regulators, particularly chromatin remodeling* Correspondence: wxm2203@xmu.edu.cn
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regulation has emerged as a distinct mechanism that
contributes to tumor development [3]. Genes encoding
subunits of ATP-dependent chromatin remodelers, espe-
cially subunits of the SWItch/Sucrose NonFermentable
(SWI/SNF) complex, are frequently mutated in a broad
array of cancer types [4].
AT-rich interactive domain-containing protein 1A
(ARID1A) is a key member of the SWI/SNF chromatin-re-
modeling complex. Also known as BAF250a, SMARCF1,
or p270, ARID1A belongs to a family of proteins that con-
tain a highly conserved, ~100 amino acid DNA binding
domain termed ARID (AT-rich interacting domain) [5].
ARID1A has been implicated in numerous protein-proteinis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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those which make ARID1A a part of SWI/SNF chromatin
remodeling complexes. As a member of SWI/SNF com-
plexes, ARID1A is thought to contribute to specific re-
cruitment of its chromatin remodeling activity by binding
transcription factors and transcriptional coactivator/core-
pressor complexes [6, 7].
Several genome-wide sequencing studies have uncov-
ered frequent ARID1A mutations in a multitude of human
cancers including subtypes of ovarian [8, 9], endometrial
[10], uterine cancers [11], gastric carcinoma [12, 13],
esophageal adenocarcinoma [14], breast cancer [15] and
transitional cell carcinoma of the bladder [16]. In liver
cancer, ARID1A mutations were observed in 10–16.8 % of
the studied tumors [17, 18] and in 13 % of hepatitis B
virus-associated hepatocellular carcinomas [19]. Further-
more, many ARID1Amutations are insertion/deletion mu-
tations, leading to downregulation of the encoded protein
[20, 21]. Immunohistochemistry assays demonstrated that
a substantial proportion of uterine endometrioid carcin-
omas, uterine clear-cell carcinomas, uterine serous carcin-
omas, and uterine carcinosarcomas also have loss of
ARID1A protein (BAF250a) [10]. In two independent co-
horts of >200 human breast cancer cases, low ARID1A
protein expression was associated with more aggressive
breast cancer phenotypes, such as those with a high tumor
grade [15]. ARID1A protein loss also correlated with an
advanced stage in non-small cell lung cancer [22]. How-
ever, the clinical significance of ARID1A and its biological
function in HCC has not yet been clarified. In the present
study, we investigated ARID1A protein expression in
HCC tissues, and analyzed the correlation between the
loss of ARID1A expression and the clinicopathological
features of HCC. In addition, we explored the possible
mechanisms by which ARID1A affects HCC metastases.
Finally, we evaluated the role of ARID1A in HCC cell mi-
gration and invasion in vitro, and conducted HCC tumor




Sixty-four patient-derived paired HCC and adjacent non-
tumorous tissue samples were collected at the Zhongshan
Hospital of Xiamen University. Written informed consent
was obtained from all patients, and the study was
approved by the Clinical Research Ethics Committee
of Zhongshan Hospital of Xiamen University.
RNA extraction and quantitative real-time reverse
transcription polymerase chain reaction
Total RNA was isolated using TRIzol® Reagent (#15596-
018, Life Technologies, New York, USA) according to
manufacturers’ instructions. Subsequently, cDNA wasgenerated using the PrimeScript™ RT reagent Kit with
gDNA eraser (Takara Bio Inc., Dalian, China), and quan-
titative real-time reverse transcription polymerase chain
reaction (qPCR) was performed using the Real-Time
PCR detection system (#7500, Applied Biosystems,
Shanghai, China) with 2× SYBR Green II/ROX qPCR
Master Mix (Takara Bio Inc.). Relative mRNA expression
was calculated using the delta threshold cycle (ΔΔCT)
method and normalized to β-actin (ACTB) expression.
The PCR primers are listed in Additional file 1: Table S1.
Immunohistochemical analysis of patient-derived HCC
tissues
Surgically excised tumor specimens were fixed in 10 %
neutral formalin and embedded in paraffin, and 4-μm
thick sections were prepared using a microtome
(#HM315, Thermo Scientific, Waltham, USA). Free-
floating section immunostaining was performed using
the avidin–biotin–peroxidase complex method (Ultra-
Sensitive™, Maixin, Fuzhou, China). Sections were depar-
affinized in xylene, and rehydrated in a graded ethanol
series. They were then placed in EDTA antigen retrieval
buffer (pH 9.0, MVS-0099 Maixin, Fuzhou, China) and
incubated at 121 °C for 3 min in an autoclave. Endogenous
peroxidase activity was blocked by placing the specimens
in 3 % hydrogen peroxide solution for 10 min. Sections
were incubated overnight at 4 °C in an anti-human
ARID1A antibody (rabbit polyclonal, 1:500, HPA005456,
Sigma, USA). Sections were stained in parallel with
non-immune immunoglobulin G as a negative control.
Antibody binding was detected using an Elivision plus
kit (Elivision™ super KIT9922, Maixin, Fuzhou, China),
which uses 3, 3’-diaminobenzidine for visualization.
Sections were counterstained with hematoxylin, then
dehydrated, and coverslips were mounted onto slide-
fixed specimens for microscopy. Slides were examined
by 2 investigators in an independent and random man-
ner. Five views per slide with 100 cells/view were evalu-
ated at 400× magnification using a light microscope
(#Axio Scope A1 pol, Carl Zeiss, Germany). Nuclear
staining was considered as positive. Immunohistochem-
ical grading was performed using the following scoring
system: 0, 0–10 %; 1, 11–29 %; 2, 30–59 %; and 3, > 60 %.
Samples had a higher score in HCC than in notumor tis-
sue were defined as ARID1A high. Otherwise, they were
be defined as ARID1A low. Hematoxylin-eosin (HE) stain
was performed as previous described [23].
Clonal cell culture and small-interfering RNA
A panel of human HCC cell lines including MHCC-
97H, LM3, SK-Hep1, SMMC-7721, HepG2, and Huh7
were purchased from the Cell Bank of Shanghai, Insti-
tutes for Biological Sciences, China. HEK293T and GP2-
293 cells were generously gifted by the Medical College
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7721 cells were cultured in Dulbecco’s Modified Eagle’s
Medium supplemented with 10 % fetal bovine serum in
a humidified incubator at 37 °C and 5 % CO2. The short
hairpin RNA (shRNA) retroviral plasmid (RNAi-Ready
pSIREN-RetroQ), which contains a puromycin resistance
gene, was purchased from Clontech. The ARID1A shRNA
sequences cloned into this vector are shown in Additional
file 1 Table S2. The full coding sequence of ARID1A was
cloned into the lentiviral pLV-CS2.0 vector that contains
an EF1α promoter to drive expression. All transfections
were performed using Turbofect Transfection Reagent
(#R0531, Thermo Scientific, Waltham, USA). Puromycin
was used to generate cells with stable knockdown of
ARID1A.
Western blotting
Total protein was extracted from cells in RIPA lysis buffer
(#P0013B, Beyotime, Shanghai, China) and quantified
using a Bradford assay. In total, 30 μg of protein was sepa-
rated using 10 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore,
Bedford, MA, USA). The membrane was blocked in a 5 %
powdered milk solution and incubated in primary anti-
body overnight at 4 °C. After washing, the membrane was
incubated with a horseradish peroxidase–conjugated sec-
ondary antibody (Santa Cruz Biotechnology, Dallas, USA.)
at 37 °C for 1 h. Protein bands were visualized using
Western Bright ECL (#K-12049-D50, Advansta, CA,
USA) and detected using ImageQuant LAS4000mini
(General Electric, USA). Relative protein levels were
calculated based on a glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) loading control. Antibodies used in-
cluded E-cadherin (#3915S, Cell Signaling technology,
Boston, USA), Vimentin (#5741S, Cell Signaling technol-
ogy), Fibronectin (#610077, BD Bioscience, Bedford, USA),
GAPDH (#AB-M-M 001, Hangzhou Xianzhi Biotechnol-
ogy, Hangzhou, China), and ARID1A (#04-080, Millipore,
Shanghai, China).
Cell migration and invasion assays
Migration of HCC cells was assessed using the 24-well
polycarbonate membrane cell migration assay kit (#3422,
Corning Incorporated Costar, Tewksbury, USA) according
to the manufacturer’s instructions. Briefly, HCC cell lines
were transfected with control and ARID1A shRNAs and
were incubated in serum-free medium for 24 h. The cells
were then transferred to the upper chamber of a Transwell
plate by seeding 2 × 105 cells per well in 200 μL serum-
free medium. Next, 0.5 mL of 10 % fetal bovine serum-
containing medium was added to the lower chamber as
a chemoattractant. Cells were incubated for 24–48 h
(depending upon migration capability) at 37 °C. Non-migrating cells on the upper membrane surface were
scraped off using cotton swabs. Cells that migrated to
the bottom of the membrane were stained with 0.1 %
crystal violet for 30 min, followed by washing with
water for 30 s to remove residual dye. Four views were
examined per transwell and cells/view were counted at
200× magnification. Each experiment was performed
in triplicate. The invasion assay was performed in a
similar fashion using BD BioCoat™ Matrigel™ Invasion
Chambers (#354480, BD Biosciences), except that the
upper chambers were precoated with ECMatrix™ gel.
Cell viability assay
Cell growth was determined using a Cell Counting Kit-8
(CCK-8) cell viability assay (#YB-K001, Yiyuan Biotech-
nologies, Guangzhou, China) according to the manufac-
turer’s instructions as described previously [24].
Cell apoptosis detection
Cell apoptosis detection was performed with Annexin
V/PI (propidiumiodide) double staining (#KGA108Key-
GEN Biotech, Nanjing, China). Briefly, 48 h after trans-
fection and 12 h Cisplatin (20 μM) treatment, cells were
harvested by 0.25 % trypsin (without EDTA), washed
twice with chilled PBS, followed by resuspension in
200 μL of binding buffer. Staining solution containing
Annexin V/FITC and PI was added to the cell suspen-
sion. After incubation in the dark for 30 min, the cells
were analyzed by FACS Gallios flow cytometer (Beckman
Coulter, USA).
Analysis of ARID1A function in HCC tumor xenografted mice
All animal protocols were approved by the Animal
Care and Use Committee of Xiamen University. We
purchased male BALB/c nude mice (4–5weeks old)
from Shanghai Experimental Animal Center of Chinese
Academic of Sciences (Shanghai, China). Animals were
kept under standard pathogen-free conditions and
allowed to acclimate for 1 week before use. MHCC-
97H cells (5 × 106/0.2 mL of PBS) stably transfected
with either control or ARID1A shRNA expression vectors
were subcutaneously injected into right flank of each
mouse (n =8 mice/group). Tumor growth was monitored
once a week using a caliper, and the tumor volume
was calculated using the following formula: volume = π/
6 × length × width2. We monitored tumor growth over an
8-week period.
Statistical analyses
The statistical package SPSS 19.0 (SPSS, Chicago, IL,
USA) was used for all analyses. All values are expressed as
mean ± SEM. Correlations of ARID1A expression with
clinicopathological characteristics were evaluated with a χ2
test using R language. Survival analyses were conducted
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Other results were analyzed using a Student’s t test. All p-
values were two-sided, and p <0.05 indicated statistical
significance
Results
Reduced expression of ARID1A in HCC patients was
associated with poor prognosis and an increased risk of
metastasis
As revealed by qPCR, ARID1A mRNA levels were signifi-
cantly downregulated in HCC tissues compared with
nontumorous tissues (n = 64, Student’s t-test, p <0.01)
(Fig. 1a). In the same 64 paired HCC samples, immuno-
histochemical analysis revealed that ARID1A protein
expression was decreased in 41 out of 64 (64.1 %)
tumor tissues when compared with adjacent non-
tumorous counterparts. And 36 out of the 41 ARID1A
protein downregulated samples also had reduced
ARID1A mRNA expression. Strong ARID1A-positive
nuclear staining was found in normal tissues (Fig. 1b,
right panel), whereas ARID1A-negative staining (dark
blue) can be seen in tumor tissues (Fig. 1b, the middle
panel). Western blotting quantification of ARID1A wasFig. 1 Recurrent reduction of ARID1A expression in hepatocellular carcinom
quantified with qPCR in 64 paired HCC (T) and nontumorous tissues (NT). H
differences between normal and cancer tissue were calculated by Student’
protein expression in HCC surgical specimens. Strong ARID1A-positive staining
staining in HCC is presented in the middle panel. Red boxes in the left panel
of the differences in the expression of ARID1A protein and mRNA between pa
survival curves of HCC patients (n = 64, all from Zhongshan Hospital of Xiame
a significantly worse prognosis than those with high ARID1A expression (log-r
in HepG2, SK-Hep1, SMMC-7721, Huh7, LM3 and MHCC-97H cell lines by west
markedly decreases its protein levels in Huh7 cells while plv cs2.0 plasmid tranconsistent with the immunohistochemical data, in which
ARID1A expression in 61.7 %(29/47) HCC tissues was sig-
nificantly lower than their adjacent nontumorous tissues
counterparts (Fig. 1c and Additional file 2: Figure S1).
After surgical resection, patients with tumors with low
ARID1A expression showed a significantly worse progno-
sis compared with those with high ARID1A expression
(log-rank test, n = 64, p = 0.042) (Fig. 1d). In addition, low
ARID1A expression in tumors was significantly correlated
with a higher metastatic rate including local lymph node
and distant metastases (Additional file 1: Table S3).
Univariate analyses of the 64 paired HCC cases indicated
that there was no significant difference in ARID1A expres-
sion according to age, sex, liver cirrhosis, hepatitis virus B
infection, or serum alfa-fetoprotein levels.
ARID1A knockdown promotes HCC cell migration and
invasion, whereas overexpression of ARID1A inhibits HCC
cell migration and invasion
In order to investigate the function of ARID1A in vitro,
we used a panel of HCC cell lines. Western blot analysis
indicated relatively high ARID1A expression in Huh7
cells, whereas MHCC-97H cells lacked ARID1A expressiona was associated with poor prognosis. a mRNA level of ARID1A was
orizontal lines indicate the median of biological replicates. Significant
s t-test (p < 0.01). b Immunohistochemistry of ARID1A (BAF250a)
in normal tissue is shown in the right panel, whereas ARID1A-negative
indicate the area enlarged in the middle and right panels. c The summary
ired tumor and non-tumor liver tissues (right panel). d Kaplan–Meier
n University) after hepatectomy. Patients with low ARID1A expression had
ank test, p = 0.042). e Endogenous expression of ARID1A was examined
ern blot. f Western blot analysis showed that ARID1A shRNA treatment
sfection significantly enhanced ARID1A expression in MHCC-97H cells
Fig. 2 Silencing of ARID1A promotes HCC cell migration and invasion. a shows cell migration ability was increased in ARID1A knockdown Huh7
cell line, while (b) exhibits its effect on invasion. For migration/invasion assay cells were cultured in the upper chamber of transwell for 24 h/48 h
respectively. c We examined epithelial–mesenchymal transition (EMT) associated proteins, including E-Cadherin, N-Cadherin, Fibronectin and
Vimentin in ARID1A knockdown Huh7 cells. d The expression level of both ARID1A and CDH1 (E-Cadherin) was evaluated by qPCR in 36 paired
HCC specimens collected from Zhongshan Hospital, Xiamen, China. Correlation coefficient (R2) of both proteins was calculated as log2-transformed
expression between normal and cancer tissues
Fig. 3 Overexpression of ARID1A inhibits HCC cells migration and invasion. a Left panel shows cell migration ability was decreased in ARID1A
overexpressed MHCC-97H cells, right panel exhibits statistical description of result A. b Cell invasive capacity was inhibited in MHCC-97H cells with
forced expression of ARID1A. c Western blot analysis showed that ARID1A transfection increased E-cadherin expression, but Vimentin was not
significantly affected
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knockdown and overexpression analyses, respectively. The
efficiencies of knockdown and overexpression in these
cells are shown in Fig. 1f.
shRNA-mediated knockdown of ARID1A signifi-
cantly promoted migration and invasion of Huh7 cells
(sh1 = 124.40 % and sh3 = 37.7 %; and sh1 = 200.2 %, and
sh3 = 100.8 %, respectively; Fig. 2a-b). To investigate the
molecular mechanism underlying the role of ARID1A
in migration and invasion, we investigated the associ-
ation of ARID1A with proteins that regulate epithelial–
mesenchymal transition. E-cadherin was significantly
downregulated in ARID1A-silenced cells (Fig. 2c), whereas
Fibronectin, N-cadherin and Vimentin expressions wereFig. 4 Downregulation of ARID1A increases in vivo xenograft tumor growth
control group (top) at the end of the experiment. Control shRNA and ARID
each group), and the tumors were isolated 8 weeks later. b ARID1A knockdow
P < 0.005). c Silencing ARID1A in HCC cells promotes its lung metastasis, left p
panel exhibits the HE image of mouse lung tissue with HCC metastasis, indicanot significantly affected (Fig. 2c). In addition, there was a
strong correlation between ARID1A and E-cadherin
(CDH1) expression in HCC tissue samples (Fig. 2d). Con-
versely, overexpression of ARID1A in MHCC-97H cells
significantly inhibited migration and invasion (Fig. 3a-b).
Furthermore, E-cadherin expression was significantly in-
creased in ARID1A overexpressing cells (Fig. 3c).
ARID1A impaired in vivo xenograft tumor growth and
HCC lung metastasis
In addition to examine the biological functions of ARID1A
in vivo, we also assessed the functions of ARID1A by using
a xenograft transplantation model in nude mice. We sub-
cutaneously transplanted the same amount of Control. a Images of xenografts in ARID1A knockdown group (bottom) and
1A shRNA cells were injected subcutaneously into nude mice (n = 8 for
n promotes xenograft growth of MHCC-97H cells in nude mice (n = 6,
anel shows the HE image of mouse lung tissue in control group, right
ted by the black arrow
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ively; thereafter we monitored the tumor growth over a
8-week period. As shown in Fig. 4a, 8 weeks after trans-
plantation, tumor growth in ARID1A knockdown trans-
planted mice was significantly greater compared with that
in control-shRNA transplanted mice (p < 0.01). Our results
exhibited the tumour growth curve on the time course after
tumor cell injection (Fig. 4.b), and the difference between
Control group and kockdown group can easily be wit-
nessed. Three out of 6 ARID1A knockdown mice developed
lung metastasis of HCC (Fig. 4c), whereas none of the mice
in the control shRNA group showed any lung metastases.
Discussion
The ARID1A gene has been classified as a novel tumor
suppressor, as evidenced by associations between ARID1A
mRNA or protein expression and several cancers in-
cluding ovarian, endometrial, gastric, and breast cancers
[10, 25]. Based on the results of a previous whole-exome
sequencing study [26], we evaluated the comprehensive
role of ARID1A in HCC.
Reduced ARID1A expression was associated with lymph
node metastasis, tumor infiltration, and poor prognosis in
patients with gastric carcinoma [27, 28]. Similarly, the
present study found that ARID1A protein expression was
decreased in patient-derived HCC tumor tissues, and that
decreased expression was significantly correlated with
lymph node and distant metastasis, and poor prognosis.
Previous studies demonstrated that ARID1A also served
as a regulator of cell proliferation and survival [22, 29]. So,
we checked its role in HCC cell proliferation and apoptosis
as well. Here, ARID1A knockdown promoted HCC cell
proliferation (Additional file 3: Figure S2-A), while
overexpression of ARID1A inhibited proliferation and
impaired clonal formation in HCC cells (Additional file 3:
Figure S2-B). These results are consistant with the previous
findings that Yi Zhang.et al. did in non-small cell lung
cancer [22]. We also evaluated a putative role of ARID1A
in mediating cisplatin-induced apoptosis in HCC cell lines,
and found that overexpression of ARID1A promoted
cisplatin-induced apoptosis (Additional file 3: Figure S2-C).
This was congruent with the findings from a previous
study that evaluated decreased ARID1A expression in
a leukemia cell line with conferred resistance to Fas-
mediated apoptosis [29].
Since epithelial-mesenchymal transition (EMT) is one
of the crucial events regulating hepatocellular carcin-
oma, prostate cancer invasion and metastasis [30, 31],
we checked EMT associated proteins in ARID1A knock-
down and overexpression cells. In our study, the expres-
sion of E-cadherin was strongly correlated with that of
ARID1A, suggesting that the two interact in some way
to regulate migration and invasion. E-cadherin is a core
protein mediated cell-cell adhesion to hold the epithelialcells tight together. Loss of E-cadherin decreases the cel-
lular adhesion, resulting in an increase of cell motility
[32]. However, ARID1A silencing did not induce epithe-
lial–mesenchymal transition in HCC cells, as evidenced by
a lack of any changes in cell morphology in HCC cell lines
subjected to ARID1A knockdown. Considering that E-
cadherin is essential for cell adhesion, it is possible that de-
creased ARID1A expression in HCC tissues might loosen
cell-cell junctions, promoting the migration and invasive
capacity of tumor cells. Additional studies are needed to
elucidate how ARID1A interacts with E-cadherin in HCC.
In nature, HCC is an invasive tumor that metastasizes
hematogenously and lymphogenously to other organs,
even after local recurrence. The most common organs of
distant metastases include the lungs, lymph nodes, bone,
and brain, with the lung metastasis occurring in 18–60 %
of HCC cases [33]. This was reflected in the present study
with the development of lung metastasis in 50 % of the
mice bearing HCC tumors with ARID1A knockdown, fur-
ther implicating decreased ARID1A expression with the
development of metastasis in HCC.
Our results,together with previous mutational and func-
tional studies, suggest ARID1A is a bona fide tumor sup-
pressor. Therefore, it will be of interest to determine
whether depletion of ARID1A can be therapeutically
exploited by targeting downstream and potentially revers-
ible epigenetic consequences of remodeler mutation [34].
Conclusion
In conclusion, our results have shown that ARID1A is fre-
quently downregulated in hepatocellular carcinoma and is
related to the aggressive phenotype of HCCs. We explored
comprehensive role of the gene in HCC, which might pro-
vide direction for future studies on the molecular mecha-
nisms of ARID1A. ARID1A represents a potential drug
candidate for molecular-targeted therapy for HCC.
Additional files
Additional file 1: Table S1. Information of qPCR Primers; Table S2.
ARID1A shRNA sequence list; Table S3. Correlation between the
clinicopathological characteristics and expression of the ARID1A (BAF250a)
protein in hepatocellular carcinoma.
Additional file 2: Figure S1. Western blot analysis of ARID1A protein
expression in 47 human HCC samples and their adjacent non-tumorous liver
tissue samples. N: non-tumorous liver tissue, T: tumor tissue.
Additional file 3: Figure S2. ARID1A depletion facilitates cell proliferation
and inhibits apoptosis. (A) CCK8 assay in Huh7 cells transfected with ARID1A
shRNA. A time dependent increase was witnessed in cell proliferation after
ARID1A shRNA transfection compared with control, but ARID1A
overexpression in MHCC-97H cells caused a decrease in cell proliferation. (B)
Colony formation assay was performed in Huh7 cells with ARID1A knockdown
and MHCC-97H cells with forced expression of ARID1A. A marked increase in
colony formation is seen in the groups with ARID1A depletion. (C) AnnexinV/PI
analysis showed that ARID1A depletion inhibited early apoptosis induced by
Cisplatin, while cells with overexpression of ARID1A are more sensitive to
Cisplatin-induced early apoptosis. (* p < 0.05, ** p < 0.01).
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